Visceral leishmaniasis as an unusual infectious complication in a patient with Crohn's disease treated with infliximab

Gastroenterol Hepatol. 2015 Jun-Jul;38(6):411-2. doi: 10.1016/j.gastrohep.2014.08.003. Epub 2014 Oct 16.

Affiliations

¹ IBD Unit, Gastroenterology and Hepatology Department, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain. Electronic address: [email protected].
² IBD Unit, Gastroenterology and Hepatology Department, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain.
³ Infectious Diseases Unit, Internal Medicine Department, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain.
⁴ Microbiology Department, Puerta de Hierro University Hospital, Majadahonda, Madrid, Spain.

PMID: 25443540
DOI: 10.1016/j.gastrohep.2014.08.003

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adrenal Cortex Hormones / adverse effects
Adrenal Cortex Hormones / therapeutic use
Adult
Amphotericin B / therapeutic use
Animals
Anti-Inflammatory Agents / adverse effects*
Anti-Inflammatory Agents / therapeutic use
Antiprotozoal Agents / therapeutic use
Crohn Disease / complications
Crohn Disease / drug therapy*
Disease Reservoirs
Disease Susceptibility
Dogs
Humans
Immunocompromised Host
Infliximab / adverse effects*
Infliximab / therapeutic use
Leishmaniasis, Visceral / diagnosis
Leishmaniasis, Visceral / drug therapy
Leishmaniasis, Visceral / etiology*
Leishmaniasis, Visceral / transmission
Male
Nephritis, Interstitial / complications
Nephritis, Interstitial / drug therapy
Opportunistic Infections / diagnosis
Opportunistic Infections / drug therapy
Opportunistic Infections / etiology*
Opportunistic Infections / transmission
Tick Bites / parasitology
Zoonoses

Substances

Adrenal Cortex Hormones
Anti-Inflammatory Agents
Antiprotozoal Agents
Amphotericin B
Infliximab